Skip to main content

Table 1 Patient characteristics

From: Intensity-modulated radiotherapy versus three-dimensional conformal radiotherapy for stage I-II natural killer/T-cell lymphoma nasal type: dosimetric and clinical results

Characteristic 3DCRT (n=47) IMRT (n=47) P value
  No. of patients (%) No. of patients (%)  
Sex    0.37
Male 35(74.5) 31(66.0)  
Female 12(25.5) 16(34.0)  
Age, years    0.37
Median range 44(20–70) 43(14–73)  
≤60 42(89.4) 39(83.0)  
>60 5(10.6) 8(17.0)  
ECOG score    0.24
0 22(46.8) 27(57.4)  
1 20(42.6) 19(40.4)  
2 5(10.6) 1(2.1)  
Stage    0.60
IE 39(83.0) 37(78.7)  
IIE 8(17.0) 10(21.3)  
B symptoms    0.10
Absent 29(61.7) 21(44.7)  
Present 18(38.3) 26(55.3)  
LDH level    0.63
Normal 35(74.5) 37(78.7)  
Elevated 12(25.5) 10(21.3)  
Primary site    0.24
Unilatera nasal cavity limited 16(34.0) 11(23.4)  
Bilateral nasal cavity limited 5(10.6) 1(2.1)  
nasal cavity lesions with limited invasion a 9(19.1) 15(31.9)  
nasal cavity lesions with extensive invasionb 10(21.3) 13(27.6)  
Non-nasal cavity originatedc 7(14.9) 7(14.9)  
mIPI    0.30
0 23(48.9) 28(59.6)  
1 20(42.6) 13(27.6)  
2-3 4(8.5) 6(12.8)  
Induction chemotherapy    <0.01
None 10(21.3) 1(2.1)  
CEOP 27(57.4) 2(4.2)  
DICE 10(21.3) 44(93.6)  
  1. anasal cavity lesions with limited invasion: the tumor invaded nasal cavity and one neighboring anatomic structure (pnasal sinus or nasopharynx).
  2. bnasal cavity lesions with extensive invasion: the tumor invaded nasal cavity and two or more neighboring anatomic structures(pnasal sinuses, nasopharynx, oropharynx or laryngopharynx).
  3. cNon-nasal cavity originated: the tumor originated from nasopharynx, oropharynx, laryngopharynx or tonsil.
  4. Abbreviations: LDH lactate dehydrogenase, ECOG Eastern Cooperative Oncology Group, mIPI Stage-modified International Prognostic Index, CEOP cyclophosphamide, epirubicin, vincristine prednisone, DICE etoposide. cyclophosphamide cisplatin, dexamethasone.